Plain-English translation of NCT05081401 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether bedaquiline, linezolid, and other newer medications can treat drug-resistant tuberculosis more effectively and in a much shorter timeframe. Researchers want to find the best combination of these drugs that works well while causing fewer side effects. The goal is to cut treatment time down from 20 months to just 9 months.
Current treatments for drug-resistant tuberculosis take nearly two years to complete, which makes it hard for patients to stick with treatment and creates challenges in healthcare systems worldwide. This medication combination was designed to work faster and be easier to take—all pills instead of injections—so more people can successfully finish their treatment.
You likely qualify if…
You likely don't qualify if…
You will take one of several all-oral medication combinations by mouth for 9 months (with a possible 2-month extension if needed). You'll have regular visits to the clinic for doctor check-ups, blood tests, chest imaging, and sputum samples to see how well the treatment is working. The trial compares your new medication combination against the current standard treatment to see which works better and causes fewer side effects.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China